<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>55</patient-age><report-id>PHFR2013GB000447</report-id><gender>male</gender><reactions><reaction>Lymphoma / diffuse large B cell non-Hodgekin's lymphoma</reaction><reaction>White blood cell was at 1.2 x10^9/L</reaction><reaction>Neutrophil count was 0.04 X10^9/L</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>CLOZARIL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ARIPIPRAZOLE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CITALOPRAM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>HALOPERIDOL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LANSOPRAZOLE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>DOCUSATE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LEVOTHYROXINE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>SENNA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>HYOSCINE</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Schizophrenia</indication><indication>Depression</indication></indications><outcomes/><country>United Kingdom</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149700_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152636</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHFR2013GB000447</safetyreportid>
		<primarysourcecountry>GB</primarysourcecountry>
		<occurcountry>GB</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-02</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-24</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHFR2013GB000447</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>Joseph</reportergivename>
			<reportermiddlename>P</reportermiddlename>
			<reporterfamilyname>Joyce</reporterfamilyname>
			<reporterorganization>Northgate Hospital</reporterorganization>
			<reporterstreet>Medical Directorate Building</reporterstreet>
			<reportercity>Morpeth</reportercity>
			<reporterstate>Northumberland</reporterstate>
			<reporterpostcode>NE61 3BP</reporterpostcode>
			<reportercountry>GB</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reportertitle>SN</reportertitle>
			<reporterfamilyname>Lynsey</reporterfamilyname>
			<reportercountry>GB</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JC</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19571221</patientbirthdate>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Depression</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Learning disability</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Lymphoma / diffuse large B cell non-Hodgekin's lymphoma</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Diffuse large B-cell lymphoma</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Diffuse large B-cell lymphoma</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>White blood cell was at 1.2 x10^9/L</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>White blood cell count decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>White blood cell count decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20130121</reactionstartdate>
				<reactionfirsttime>1274</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Neutrophil count was 0.04 X10^9/L</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Neutrophil count decreased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Neutrophil count decreased</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20130121</reactionstartdate>
				<reactionfirsttime>1274</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20130121</testdate>
				<testname>Neutrophil count</testname>
				<testresult>0.04</testresult>
				<testunit>10^9/L</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20130121</testdate>
				<testname>White blood cell count</testname>
				<testresult>1.20</testresult>
				<testunit>10^9/L</testunit>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>CLOZARIL</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationnumb>19-758</drugauthorizationnumb>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Schizophrenia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2009-07-28</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>CLOZAPINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diffuse large B-cell lymphoma</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Diffuse large B-cell lymphoma</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neutrophil count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Neutrophil count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>White blood cell count decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>White blood cell count decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ARIPIPRAZOLE</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugstructuredosagenumb>15</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>15 mg daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>ARIPIPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CITALOPRAM</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugstructuredosagenumb>20</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>20 mg daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Depression</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>CITALOPRAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>HALOPERIDOL</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugstructuredosagenumb>15</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>15 mg, PRN</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HALOPERIDOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LANSOPRAZOLE</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugstructuredosagenumb>30</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>30 mg daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LANSOPRAZOLE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>DOCUSATE</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>400 mg daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DOCUSATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LEVOTHYROXINE</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugstructuredosagenumb>50</drugstructuredosagenumb>
				<drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
				<drugdosagetext>50 ug daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>SENNA</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugstructuredosagenumb>7.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>7.5 mg daily</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>SENNA ALEXANDRINA</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>HYOSCINE</medicinalproduct>
				<obtaindrugcountry>GB</obtaindrugcountry>
				<drugauthorizationcountry>GB</drugauthorizationcountry>
				<drugstructuredosagenumb>.5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>0.5 mg daily</drugdosagetext>
				<drugadministrationroute code="061">Topical</drugadministrationroute>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYOSCINE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHFR2013GB000447, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>02 Jan 2013 with follow up report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 02 Jan 2013 with follow up report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 11 Jan 2013 with follow up report received from <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 22 Jan 2013 with follow up report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 24 Jan 2013. This report refers to a 56-year old male patient (CPMS No: 790762). Medical history included <Semaphore x="1842410" class="Procedure" value="Depression After Stopping Dexamethasone" score="1.00" ID="C113456">depression </Semaphore>and mild to moderate <Semaphore x="3063037" class="MedDRA LLT" value="Learning disability" score="1.00" ID="10024092">learning disability</Semaphore>. This polymedicated patient received <Semaphore x="385527" class="Medicine" value="Clozaril" score="0.87" ID="247865">Clozaril </Semaphore>(<Semaphore x="385490" class="Medicine" value="Clozapine" score="0.49" ID="252210">clozapine</Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="3241259" class="MedDRA LLT" value="Schizophrenia" score="1.00" ID="10039626"><Semaphore x="2499616" class="Disease or Finding" value="Schizophrenia" score="1.00" ID="C3362">schizophrenia </Semaphore>at an unspecified </Semaphore>dose from 28 Jul 2009. On an unspecified date, the patient had <Semaphore x="2141674" class="Disease or Finding" value="Lymphoma" score="1.00" ID="C3208">lymphoma</Semaphore>. The patient would commence <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy </Semaphore>next week, the list of <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drugs </Semaphore>included <Semaphore x="1142733" class="Medicine" value="rituximab" score="0.49" ID="213126">rituximab</Semaphore>, <Semaphore x="423236" class="Medicine" value="Cyclophosphamide" score="0.49" ID="243141">cyclophosphamide</Semaphore>, <Semaphore x="507241" class="Medicine" value="DOXOrubicin" score="0.49" ID="259834">doxorubicin</Semaphore>, <Semaphore x="1330555" class="Medicine" value="vinCRIStine" score="0.49" ID="196844">vincristine</Semaphore>, <Semaphore x="1081705" class="Medicine" value="prednisoLONE" score="0.49" ID="291320">prednisolone</Semaphore>, <Semaphore x="678897" class="Medicine" value="Hydrocortisone" score="0.49" ID="270908">hydrocortisone</Semaphore>, <Semaphore x="346535" class="Medicine" value="Chlorpheniramine" score="0.49" ID="250263">chlorpheniramine</Semaphore>, <Semaphore x="950292" class="Medicine" value="Ondansetron" score="0.49" ID="252193">ondansetron </Semaphore>and <Semaphore x="869115" class="Medicine" value="Metoclopramide" score="0.49" ID="280139">metoclopramide</Semaphore>. The patient received <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy </Semaphore>(<Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drugs </Semaphore>unspecified) <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>from 10 Jan 2013 for 18 weeks. On 21 Jan 2013, the patient's laboratory data showed that, <Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939"><Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939"><Semaphore x="1606939" class="Procedure" value="Blood Cell Count" score="1.00" ID="C28133">white <Semaphore x="1606939" class="Procedure" value="Blood Cell Count" score="1.00" ID="C28133">blood cell </Semaphore></Semaphore>
      <Semaphore x="1606939" class="Procedure" value="Blood Cell Count" score="1.00" ID="C28133">
       </Semaphore></Semaphore>
     <Semaphore x="1606939" class="Procedure" value="Blood Cell Count" score="1.00" ID="C28133">
      <Semaphore x="2803177" class="MedDRA LLT" value="Blood count" score="1.00" ID="10064196">(<Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939"><Semaphore x="1606939" class="Procedure" value="Blood Cell Count" score="1.00" ID="C28133">WBC</Semaphore>) count </Semaphore></Semaphore></Semaphore>
     </Semaphore>was 1.2 x 10^9/L and <Semaphore x="2110173" class="Procedure" value="Leukocyte Count" score="1.00" ID="C51948">neutrophil count </Semaphore>was 0.04 x 10^9/L. The patient was on day eight <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemo </Semaphore>cycles. It was reported that, <Semaphore x="1993453" class="Procedure" value="Granulocyte Colony Stimulating Factor Measurement" score="1.00" ID="C82018">granulocyte colony stimulating factor </Semaphore>(G <Semaphore x="1747820" class="AnatomicStructure" value="Cerebrospinal Fluid" score="1.00" ID="C12692">CSF </Semaphore>or <Semaphore x="1993453" class="Procedure" value="Granulocyte Colony Stimulating Factor Measurement" score="1.00" ID="C82018">GCSF</Semaphore>) planned for patient on 7, 11 and 14 day of cycle. Upon follow up, <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>reported that patient had diffuse large <Semaphore x="1562958" class="Disease or Finding" value="B-Cell Non-Hodgkin Lymphoma" score="1.00" ID="C3457">B cell <Semaphore x="3145381" class="MedDRA LLT" value="Non-Hodgkin's lymphoma" score="1.00" ID="10029547">non <Semaphore x="2028219" class="Disease or Finding" value="Hodgkin Lymphoma" score="1.00" ID="C9357">Hodgkin's lymphoma</Semaphore></Semaphore></Semaphore>. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>with <Semaphore x="385527" class="Medicine" value="Clozaril" score="0.87" ID="247865">Clozaril </Semaphore>was ongoing. The seriousness criterion and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events were not reported. The causality of the event diffuse large <Semaphore x="1562958" class="Disease or Finding" value="B-Cell Non-Hodgkin Lymphoma" score="1.00" ID="C3457">B cell <Semaphore x="3145381" class="MedDRA LLT" value="Non-Hodgkin's lymphoma" score="1.00" ID="10029547">non <Semaphore x="2028219" class="Disease or Finding" value="Hodgkin Lymphoma" score="1.00" ID="C9357">Hodgkin's lymphoma </Semaphore></Semaphore></Semaphore>was reported as not suspected with <Semaphore x="385527" class="Medicine" value="Clozaril" score="0.87" ID="247865">Clozaril</Semaphore>. The causality of other events was not reported.Follow up report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 02 Jan 2013: Updated patient's demographic detail's (date of birth and age) and suspect product information (indication and start date).Follow up report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 11 Jan 2013: Updated <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>for the event.Follow up report received from <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>on 22 Jan 2013: Updated laboratory data (for dated 21 Jan 2013) and added the events (<Semaphore x="3320985" class="MedDRA LLT" value="White blood cell count decreased" score="1.00" ID="10047942"><Semaphore x="3320985" class="MedDRA LLT" value="White blood cell count decreased" score="1.00" ID="10047942"><Semaphore x="2110489" class="Disease or Finding" value="Leukopenia" score="1.00" ID="C26816"><Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939"><Semaphore x="2110173" class="Procedure" value="Leukocyte Count" score="1.00" ID="C51948"><Semaphore x="1606939" class="Procedure" value="Blood Cell Count" score="1.00" ID="C28133">white <Semaphore x="3142841" class="MedDRA LLT" value="Neutrophil count decreased" score="1.00" ID="10029366">blood cell </Semaphore></Semaphore>
         </Semaphore>
        </Semaphore>
       <Semaphore x="2308242" class="Disease or Finding" value="Neutropenia" score="1.00" ID="C80520">decreased </Semaphore></Semaphore>
      <Semaphore x="3142841" class="MedDRA LLT" value="Neutrophil count decreased" score="1.00" ID="10029366">
       </Semaphore></Semaphore>
     <Semaphore x="3142841" class="MedDRA LLT" value="Neutrophil count decreased" score="1.00" ID="10029366">
      <Semaphore x="2308242" class="Disease or Finding" value="Neutropenia" score="1.00" ID="C80520">and <Semaphore x="2308242" class="Disease or Finding" value="Neutropenia" score="1.00" ID="C80520">neutrophil count </Semaphore></Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="3142841" class="MedDRA LLT" value="Neutrophil count decreased" score="1.00" ID="10029366">decreased</Semaphore>).Follow up report received from <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>on 24 Jan 2013: Updated reporter's information, medical history, suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>information and event with causality (<Semaphore x="1850969" class="Disease or Finding" value="Diffuse Large B-Cell Lymphoma" score="1.00" ID="C8851"><Semaphore x="3145381" class="MedDRA LLT" value="Non-Hodgkin's lymphoma" score="1.00" ID="10029547">lymphoma with diffuse </Semaphore>large B <Semaphore x="2141438" class="Procedure" value="Lymphoma Cell Count" score="1.00" ID="C74613">cell lymphoma</Semaphore></Semaphore>). Added concomitant medications.</narrativeincludeclinical>
				<sendercomment>Event diffuse large B cell lymphoma is not consistent with known pharmacology of clozapine. However, review of available reported data does not allow for a proper causality assessment. In the presence of confounders that include chemotherapy, the events white blood cell count decreased and neutrophil count decreased are not assessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>